Healthcare entity
Novo Nordisk is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. Coverage clusters in market-trends, which accounts for 4 of those 6, with the remainder spread across 2 other categories. That works out to roughly 0.2 stories per week across a 176-day span.
Last mentioned: Aug 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 16 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Novo Nordisk is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. Coverage clusters in market-trends, which accounts for 4 of those 6, with the remainder spread across 2 other categories. That works out to roughly 0.2 stories per week across a 176-day span. Sentiment skews less negative than the wider beat, at 17% negative against 24% across all 1051 Healthcare stories in the same window. The 6.2 average consequence score is above the beat benchmark of 6 in the same window. Each story carries 3 original sources on average, compared with 3.4 for the broader beat in this window. We currently track 6 Healthcare stories that mention Eli Lilly and Company, published between March 3, 2026 and August 25, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 1051 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eli Lilly and Company. Shared-story counts are live from our verified record — not editorial picks.
Expected FDA submission
Lilly plans to file retatrutide for FDA approval.
2026 interim results and 2030 vision announced
Innovent announces strong H1 2026 growth and sets a new strategic goal to become a global premier biopharma.
Early access program announced
Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
80-week trial results released
Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.
Off-Label Drug Mandate
The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process.
Vida Health Assessment
Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse.
Employer Imposes Vida Health Requirement
Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits.
Zepbound Prescription Issued
David Davis receives a prescription for Zepbound from his primary care doctor to treat obstructive sleep apnea.
Revenue surpasses RMB 10 billion
Innovent reports full-year revenue over RMB 10 billion and full-scale profitability.
Global partnership wave begins
Over the next ten months, Innovent reaches collaborations with Takeda, Eli Lilly, Pfizer, Ollin, and Spero.
Second transformation begins
Innovent moves from a long-term investment phase toward full profitability and scale.
Full value-chain capability established
Innovent completes the first transformation spanning R&D, manufacturing, and commercialization.
First transformation begins
Innovent starts shifting from an R&D-driven biotech into a biopharmaceutical company with full value-chain capabilities.
Innovent's H1 2026 update signals a push from China regional champion to global biopharma with a 20+ asset partnered pipeline across oncology, autoimmune, cardiovascular/metabolic, and ophthalmology. Healthcare leaders should track how these global partnerships reshape care access and innovation.
Source: prnewswire.com · manilatimes.net
Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Source: gdnonline.com · 933thedrive.com
The suit ensures obesity patients receive the latest efficacy data, as Novo contends Lilly’s ads deny consumers a full picture of treatment options, potentially swaying prescriptions.
Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Source: Business News India · Mint
A California man’s employer-mandated use of Vida Health stalled his Zepbound treatment for obstructive sleep apnea, highlighting how telehealth platforms are overriding primary care physicians to reduce obesity drug costs.
Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Source: Bbns · The Lincolnian Online
Eli Lilly and Company is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
